Blockade of CCR5-mediated myeloid derived suppressor cell accumulation enhances anti-PD1 efficacy in gastric cancer

Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer

(2017) Prabhsimranjot Singh et al.   Journal of Hematology & Oncology

Global cancer statistics, 2012

(2015) Lindsey A. Torre et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Deficiency of CC chemokine ligand 2 and decay-accelerating factor causes retinal degeneration in mice

(2015) Minzhong Yu et al.   EXPERIMENTAL EYE RESEARCH

Subsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice

(2014) J.-I. Youn et al.   JOURNAL OF IMMUNOLOGY

Disruption of CCR5-Dependent Homing of Regulatory T Cells Inhibits Tumor Growth in a Murine Model of Pancreatic Cancer

(2014) M. C. B. Tan et al.   JOURNAL OF IMMUNOLOGY

IL-18 Enhances Immunosuppressive Responses by Promoting Differentiation into Monocytic Myeloid-Derived Suppressor Cells

(2014) Hui Xuan Lim et al.   JOURNAL OF IMMUNOLOGY

Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 Efficacy

(2014) S. L. Highfill et al.   Science Translational Medicine

Increase in CD14+HLA-DR−/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis

(2013) Fumitaka Arihara et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Increased CD14+HLA-DR-/low myeloid-derived suppressor cells correlate with extrathoracic metastasis and poor response to chemotherapy in non-small cell lung cancer patients

(2013) Ang Huang et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Tumor-Immune Dynamics Regulated in the Microenvironment Inform the Transient Nature of Immune-Induced Tumor Dormancy

(2013) K. P. Wilkie et al.   CANCER RESEARCH

The Continuum of Cancer Immunosurveillance: Prognostic, Predictive, and Mechanistic Signatures

(2013) Jérôme Galon et al.   IMMUNITY

Nivolumab plus Ipilimumab in Advanced Melanoma

(2013) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Myeloid-derived suppressor cells in transplantation and cancer

(2012) Jordi C. Ochando et al.   IMMUNOLOGIC RESEARCH

Tumor-Infiltrating Monocytic Myeloid-Derived Suppressor Cells Mediate CCR5-Dependent Recruitment of Regulatory T Cells Favoring Tumor Growth

(2012) E. Schlecker et al.   JOURNAL OF IMMUNOLOGY

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13

(2011) Rachel F. Gabitass et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity

(2010) Suzanne Ostrand-Rosenberg   CANCER IMMUNOLOGY IMMUNOTHERAPY

Opposing Effects of Toll-like Receptor (TLR3) Signaling in Tumors Can Be Therapeutically Uncoupled to Optimize the Anticancer Efficacy of TLR3 Ligands

(2010) R. Conforti et al.   CANCER RESEARCH

Antitumor Immunity and Cancer Stem Cells

(2009) Tobias Schatton et al.   Annals of the New York Academy of Sciences

Myeloid-Derived Suppressor Cells Inhibit T-Cell Activation by Depleting Cystine and Cysteine

(2009) M. K. Srivastava et al.   CANCER RESEARCH

Gastric cancer

(2009) Henk H Hartgrink et al.   LANCET

Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapy

(2008) C. Marcela Diaz-Montero et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY